Reirradiation of recurrent salivary gland malignancies with fractionated stereotactic body radiation therapy
Tóm tắt
The purpose of this study was to review a single-institution experience with the reirradiation of recurrent salivary gland tumors using fractionated stereotactic radiosurgery (SBRT). Between 2003 and 2011, 18 patients diagnosed with recurrent, previously irradiated, salivary gland carcinomas were treated with SBRT reirradiation. Median age was 68 for all patients with most tumors being of major salivary gland origin. Most patients did not undergo surgical resection, and among those that did, all had positive margins. Only seven patients received chemotherapy, and the median SBRT dose was 30 Gy given in five fractions with a median cumulative dose of 91.1 Gy. The median overall survival (OS), progression-free survival (PFS), and local control (LRC) were 11.5, 3.5, and 5.5 months, respectively. The 2-year OS, PFS, and LRC rates were 39%, 24%, and 53%, respectively. Statistical analysis identified presence of gross disease and interval to reirradiation as negative predictors of survival outcomes on both univariate and multivariate analyses (p < 0.05). On multivariate analysis, tumor volume was a negative predictor of survival outcomes (p < 0.05). Long-term toxicity analysis revealed four patients in the reirradiated group with soft tissue necrosis, which correlated with the cumulative dose (p = 0.01). Our data suggest that SBRT is a reasonable treatment option for reirradiation of salivary gland tumors, but further studies are warranted.
Tài liệu tham khảo
Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L (2010) Major and minor salivary gland tumors. Crit Rev Oncol Hematol 74(2):134–148
Chen AM, Granchi PJ, Garcia J, Bucci MK, Fu KK, Eisele DW (2007) Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 67(4):982–987
Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB (2005) Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 103(12):2544–2550
Sakata K, Aoki Y, Karasawa K, Nakagawa K, Hasezawa K, Muta N et al (1994) Radiation therapy for patients of malignant salivary gland tumors with positive surgical margins. Strahlenther Onkol 170(6):342–346
Garden AS, Weber RS, Ang KK, Morrison WH, Matre J, Peters LJ (1994) Postoperative radiation therapy for malignant tumors of minor salivary glands. Outcome and patterns of failure. Cancer 73(10):2563–2569
Chen AM, Garcia J, Bucci MK, Chan AS, Kaplan MJ, Singer MI et al (2008) Recurrent salivary gland carcinomas treated by surgery with or without intraoperative radiation therapy. Head Neck 30(1):2–9
Pederson AW, Haraf DJ, Blair EA, Stenson KM, Witt ME, Vokes EE et al (2010) Chemoreirradiation for recurrent salivary gland malignancies. Radiother Oncol 95(3):308–311
Douglas JG, Koh WJ, Austin-Seymour M, Laramore GE (2003) Treatment of salivary gland neoplasms with fast neutron radiotherapy. Arch Otolaryngol Head Neck Surg 129(9):944–948
Douglas JG, Goodkin R, Laramore GE (2008) Gamma knife stereotactic radiosurgery for salivary gland neoplasms with base of skull invasion following neutron radiotherapy. Head Neck 30(4):492–496
Lee N, Millender LE, Larson DA, Wara WM, McDermott MW, Kaplan MJ et al (2003) Gamma knife radiosurgery for recurrent salivary gland malignancies involving the base of skull. Head Neck 25(3):210–216
Gibbs IC, Levendag PC, Fariselli L, Bondiau PY, Lartigau E, Loo BW Jr (2009) Re: “The safety and efficacy of robotic image-guided radiosurgery system treatment for intra- and extracranial lesions: a systematic review of the literature” [Radiotherapy and Oncology 89 (2009) 245-253]. Radiother Oncol 93(3):656–657
Argiris A, Haraf DJ, Kies MS, Vokes EE (2003) Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist 8(4):350–360
Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun RJ et al (2008) Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 26(34):5518–5523
De Crevoisier R, Bourhis J, Domenge C, Wibault P, Koscielny S, Lusinchi A et al (1998) Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 16(11):3556–3562
Chen AM, Farwell DG, Luu Q, Cheng S, Donald PJ, Purdy JA (2011) Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 80(3):669–676
Surakanti SG, Agulnik M (2008) Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol 35(3):309–319
Schoenfeld JD, Sher DJ, Norris CM Jr, Haddad RI, Posner MR, Balboni TA et al (2012) Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys 82(1):308–314
Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D et al (2009) Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg 135(7):687–692
Salama JK, Vokes EE, Chmura SJ, Milano MT, Kao J, Stenson KM et al (2006) Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 64(2):382–391
Watkins JM, Shirai KS, Wahlquist AE, Stuart RK, Chaudhary UB, Garrett-Mayer E et al (2009) Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck 31(4):493–502
Unger KR, Lominska CE, Deeken JF, Davidson BJ, Newkirk KA, Gagnon GJ et al (2010) Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 77(5):1411–1419